ABMC Products To Be Used By The French Ministry Of Interior
KINDERHOOK, N.Y.--(BUSINESS WIRE)--American Bio Medica Corporation (NASDAQ:ABMC) announced today that they have been awarded, through their master European distributor, MAVAND Solutions GmbH, a government tender with the French Ministry of Interior. Effective immediately, the police force will begin using ABMC's patent pending Rapid STAT oral fluid point of collection test to detect the presence or absence of narcotics in French motorists. Based on information contained within the tender, over the next 3 years, ABMC expects the Ministry of Interior to use approximately 900,000 units.
In an interview dated July 2, 2008, the French Minister of the Interior, Michèle Alliot-Marie stated that they expect 50,000 tests to be distributed to the police force this summer. Alliot-Marie stated that the selected product was chosen after a series of tests beginning close to two years ago and that the Ministry chose the most reliable product. It was also noted that the Ministry opted to use oral fluid testing due to its convenience and less evasive nature.
ABMC Chief Executive Officer Stan Cipkowski stated, "This is great news for ABMC and our master European distributor. This award will of course have a positive impact on our 2008 sales and our sales over the next couple of years." Cipkowski added, "The study conducted by the French Ministry of Interior, in both the field and the laboratory, focused on accuracy, sensitivity, specificity and ease of use and involved virtually every oral fluid testing device on the market. When we launched Rapid STAT in the fourth quarter of 2007, we indicated that it was ideal for the roadside testing market and the fact that the Rapid STAT was the product chosen is proof of its suitability for such markets."
The Rapid STAT oral fluid test combines the patented benefits of ABMC's OralStat oral fluid device with ABMC's urine based Rapid TOX cassette. The Rapid STAT maximizes drug recovery, provides a transport container for confirmation of positive results and provides the lowest marijuana testing sensitivity available.
For more information on American Bio Medica Corporation or its products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One, Rapid TEC, RDS InCup, Rapid TOX and Rapid TOX Cup products test for the presence or absence of drugs of abuse in urine, while OralStat and Rapid STAT tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development, regulatory approvals and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2007, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.
Copyright 2008 Business Wire All Rights Reserved.